Rheumatoid Arthritis CRISPR Knockout Cell Models for Drug Discovery

Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting approximately 0.5-1% of the global adult population, with an estimated 18 million cases worldwide in 2019 (WHO Global Health Estimates). The disease is more prevalent in women (2-3 times higher than men) and typically onsets between 40-60 years of age. RA leads to progressive joint destruction, disability, and increased cardiovascular mortality. The 5-year survival rate for RA patients with severe disease is approximately 80%, compared to 90% in the general population (NCI SEER data, adjusted for RA-related comorbidities). Key risk factors include genetic predisposition (HLA-DRB1 shared epitope), smoking, and hormonal factors.

RA is an ideal model for studying autoimmune-driven inflammatory arthritis due to its well-characterized synovial pathology, defined autoantibody profiles (rheumatoid factor, anti-CCP), and availability of public transcriptomic and proteomic datasets (e.g., GEO, ArrayExpress). Open questions include the mechanisms of fibroblast-like synoviocyte (FLS) activation, the role of epigenetic modifications, and the transition from acute to chronic inflammation. Gene-edited cell models enable precise dissection of these pathways.

The pathogenesis of RA involves a complex interplay of immune cells and synovial fibroblasts. Key pathways include:

• • NF-kB Pathway: Activation by TNF-alpha and IL-1 leads to transcription of pro-inflammatory cytokines (IL-6, IL-8) and matrix metalloproteinases (MMPs).
• • JAK-STAT Pathway: Cytokine receptor signaling (e.g., IL-6, IFN-gamma) activates JAKs, which phosphorylate STATs, driving gene expression for cell proliferation and inflammation.
• • MAPK Pathway: ERK, JNK, and p38 MAPKs mediate FLS proliferation and cytokine production in response to stress and growth factors.
• • PI3K/AKT/mTOR Pathway: Promotes FLS survival, migration, and resistance to apoptosis.

While RA is not a monogenic disease, genome-wide association studies (GWAS) and sequencing have identified risk variants and somatic mutations in synovial tissue. The table below summarizes key genetic associations (data from GWAS Catalog, NCBI Gene, and literature meta-analyses).

• • Key deregulated networks in RA FLS include:
• • Wnt/beta-catenin pathway: Promotes FLS proliferation and bone erosion. Key nodes: Wnt5a, Frizzled receptors, beta-catenin.
• • RANKL/RANK/OPG axis: Drives osteoclastogenesis and bone resorption. RANKL is overexpressed in RA synovium.
• • Hypoxia-inducible factor (HIF) pathway: Under hypoxic joint conditions, HIF-1alpha upregulates VEGF, promoting angiogenesis.
• • Notch signaling: Notch1 and Notch3 are upregulated in FLS, contributing to invasion and cytokine production.

Commonly used cell lines for RA research include:

Organoid models derived from RA synovial tissue (synovial organoids) recapitulate the 3D architecture and cellular heterogeneity, including FLS, macrophages, and T cells, enabling more physiologically relevant drug testing.

• • Animal models for RA include:
• • Collagen-induced arthritis (CIA): Most common model; immunization with type II collagen induces polyarthritis in DBA/1 mice.
• • K/BxN serum-transfer model: Rapid, reproducible arthritis induced by injection of serum from K/BxN mice.
• • TNF-alpha transgenic mice: Overexpress human TNF-alpha, developing spontaneous arthritis.
• • SKG mice: ZAP-70 mutation leads to autoimmune arthritis.
• • Humanized mouse models (e.g., NSG-SGM3): Engrafted with human immune cells and synovial tissue for preclinical testing.

• • CRISPR-Cas9 gene editing enables the creation of isogenic cell models to study RA-specific genes. Examples include:
• • TNFAIP3 knockout in MH7A cells: Mimics the loss of A20, leading to constitutive NF-kB activation and increased cytokine production.
• • PTPN22 R620W knock-in in THP-1 cells: Models the autoimmune risk variant to study altered T-cell signaling.
• • IL6 knockout in SW982 cells: Used to assess the role of IL-6 in FLS activation.

Commercially available, sequence-verified gene-edited cell models (e.g., CRISPR knockout and knock-in lines) accelerate research by providing reproducible, isogenic backgrounds for functional studies and drug screening.

• • Knockout and knock-in lines are used to validate the role of GWAS-identified risk genes in RA. For example:
• • TNFAIP3 knockout in FLS: Confirmed that loss of A20 enhances MMP production and invasiveness, supporting its role as a disease modifier.
• • PTPN22 R620W knock-in in T cells: Demonstrated altered TCR signaling and increased autoreactivity, validating the variant's functional impact.

Isogenic pairs (e.g., wild-type vs. TNFAIP3-knockout FLS) are used to screen for compounds that selectively inhibit the hyperactivated NF-kB pathway. Resistance mechanisms to JAK inhibitors (e.g., tofacitinib) can be modeled by generating JAK1 or JAK2 knockout lines and assessing compensatory signaling via STAT3.

CRISPR-based synthetic lethality screens in FLS can identify genes that become essential under inflammatory conditions. For instance, screening a genome-wide knockout library in TNF-alpha-stimulated FLS can reveal targets whose loss sensitizes cells to apoptosis, providing new therapeutic avenues.